Umoja Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 08:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T...
Umoja Biopharma Announces Oral Presentation at the 65th American Society of Hematology Annual Meeting
November 02, 2023 09:43 ET
|
Umoja Biopharma, Inc.
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced that...
Umoja Biopharma to Present at the 2023 Cell & Gene Meeting on the Mesa
October 05, 2023 14:30 ET
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced that...
Umoja Biopharma’s VivoVec Platform Presents Encouraging Proof-of-Concept Data in Ongoing Non-Human Primate Study at the 8th CAR-TCR Summit
September 01, 2023 12:30 ET
|
Umoja Biopharma, Inc.
Preliminary data from ongoing preclinical study include rapid, durable chimeric antigen receptor (CAR) T cell generation in vivo after a single infusion of VivoVec particles Additional data to be...
Umoja Biopharma to Unveil Preliminary Positive Non-Human Primate Data for the First Time at the 8th CAR-TCR Summit
August 23, 2023 10:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for cancers, today announced it will unveil preliminary...
Umoja Biopharma to Present New Data at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 03, 2023 08:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid...